TolerRx Announces Manufacturing and Supply Agreement with Abbott
News Nov 30, 2005
TolerRx has announced that it has entered into an agreement with Abbott for the manufacturing of TolerRx's TRX4 monoclonal antibody.
Under the terms of the agreement, Abbott will perform scale-up and GMP manufacturing of TRX4 for use in clinical trials, as well as supply commercial-grade material to support regulatory submissions and potential commercial launch.
"With the recent efficacy data with TRX4 in type 1 diabetes and our ongoing clinical trials in subjects with type 1 diabetes and psoriasis, this agreement positions TolerRx to ensure adequate supply of TRX4 for pivotal clinical studies and, if approved, for commercial sale," stated Douglas J. Ringler, V.M.D., President and CEO of TolerRx.
"In this regard, we are delighted to have Abbott, a company with demonstrated experience and expertise in the manufacturing of monoclonal antibody products, as our manufacturer."
"There is synergy between Abbott's experience, capacity, and technical expertise and TolerRx's manufacturing needs," stated Mark O' Mahony, Director of Process Development, Manufacturing and Quality Control for TolerRx.
"We look forward to working with one of the world's leading health care companies as our manufacturer of TRX4."
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.